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The focal adhesion kinase (FAK) and cell adhesion
kinase  (CAK, PYK2, CADTK, RAFTK) are highly ho-
mologous FAK family members, yet clearly have unique
roles in the cell. Comparative analyses of FAK and CAK
have revealed intriguing differences in their activities.
These differences were investigated further through the
characterization of a set of FAK/CAK chimeric kinases.
CAK exhibited greater catalytic activity than FAK
in vitro, providing a molecular basis for differential sub-
strate phosphorylation by FAK and CAK in vivo. Fur-
thermore, the N terminus may regulate catalytic activ-
ity since chimeras containing the FAK N terminus and
CAK catalytic domain exhibited a striking high level of
catalytic activity and substrate phosphorylation. Unex-
pectedly, a modulatory role for the N termini in subcel-
lular localization was also revealed. Chimeras contain-
ing the FAK N terminus and CAK C terminus localized
to focal adhesions, whereas chimeras containing the N
and C termini of CAK did not. Finally, prominent
changes in cell morphology were induced upon expres-
sion of chimeras containing the CAK N terminus,
which were not associated with apoptotic cell death, cell
cycle progression delay, or changes in Rho activity.
These results demonstrate novel regulatory roles for the
N terminus of FAK family kinases.
Focal adhesion kinase (FAK)1 and cell adhesion kinase 
(CAK, also known as PYK2, CADTK, or RAFTK) constitute
the FAK family of cytoplasmic tyrosine kinases. The structural
features of this family include large N- and C-terminal domains
that flank a central tyrosine kinase domain (1). The sequences
of FAK and CAK are 45% identical and 65% similar. The
greatest homology exists between the catalytic domains (60%
identity) and the extreme C termini, which corresponds to the
region of FAK that directs subcellular localization (62% iden-
tity) (2). Regions within the N termini of both kinases have
homology with the band 4.1/ERM family of proteins within a
region known as the FERM domain (3). In addition, FAK and
CAK share conserved phosphorylated tyrosines and C-termi-
nal proline-rich regions that mediate interactions with SH2-
and SH3-containing proteins (4).
FAK is expressed in nearly all tissues and cell types, and in
a wide variety of adherent cells FAK is discretely localized to
focal adhesions (5, 6). In contrast, CAK expression is re-
stricted mainly to the brain and hematopoetic cells, and its
subcellular localization is cell type-specific (4). In some cells,
CAK is localized to focal adhesions or focal adhesion-like
structures (7, 8). CAK has also been localized to specialized
actin-containing structures such as the podosomes of macro-
phages, the sealing zone of osteoclasts, and along stress fibers
in smooth muscle cells (9–11). It is also targeted to membrane
ruffles and lamellipodia in some spreading and motile cells (12,
13). Alternatively, CAK staining has been described as dif-
fuse, perinuclear, or colocalized with the Golgi (7, 14–17). The
differential subcellular localization of FAK and CAK may
underscore important differences in biological function.
Focal adhesion targeting of FAK is mediated by conserved
sequences within the C terminus, designated the Focal Adhe-
sion Targeting (FAT) sequence (18), which shares extensive
homology with the C terminus of CAK. The C-terminal non-
catalytic domain of CAK localizes discretely to focal adhesions
when autonomously expressed (7, 19). Since full-length CAK
exhibits focal adhesion localization in only a subset of cells, a
functional FAT sequence in the C terminus of CAK appears to
be masked in some cell types. This suggests that focal adhesion
localization may be regulated on multiple levels.
FAK is primarily activated through integrin-mediated cell
adhesion to an insoluble extracellular matrix. To a lesser ex-
tent, FAK is activated by growth factors, neuropeptides, and
bioactive lipids (20). Conversely, activation of CAK occurs
largely in response to soluble extracellular factors, including
signals that act through G-protein-coupled receptors, cyto-
kines, antigen receptors, and stress signals (4). CAK is max-
imally activated in response to integrin-mediated cell adhesion
in only a subset of cells including hematopoetic cells (8, 21, 22).
However, in many other cells, adhesion induces a slight in-
crease in tyrosine phosphorylation (7, 14, 23). Many of the
stimuli that activate CAK also elevate intracellular calcium
levels, and in fact, CAK activation is dependent upon the
presence of calcium (24–26). Interestingly, a chimeric protein
consisting of the N terminus and catalytic domain of CAK
fused to the C terminus of FAK was driven to focal adhesions
and was strongly regulated by adhesion to fibronectin (14). The
positive correlation between focal adhesion localization and
activation by integrin-mediated adhesion has been reported in
the literature and highlights a potential mechanism for differ-
ential regulation of FAK and CAK activity (27, 28).
Although the signals that lie upstream of FAK family ki-
nases may differ, many of the immediate consequences of acti-
vation are conserved. These include recruitment of SH2 do-
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main containing signaling molecules such as Src and Grb2 into
complex with the kinase, and tyrosine phosphorylation of cy-
toskeleton-associated adaptor proteins, such as paxillin and
p130cas (1). Signaling via FAK and CAK is also involved in the
activation of MAP kinase family members (4, 20). These data
suggest that differential regulation of common signaling events
downstream of FAK and CAK are important for biological
function.
Since FAK and CAK trigger tyrosine phosphorylation of
some common substrates, it may be predicted that the biolog-
ical outcomes of FAK/CAK signaling would be similar as well.
In fact, both kinases have been implicated in the processes of
cell spreading, focal adhesion turnover, and migration (1, 9, 13,
29, 30). Despite this commonality, FAK and CAK clearly have
divergent functions as well. The two kinases have opposing
effects on cell cycle progression, whereas FAK accelerates pro-
gression into S phase, CAK delays this transition (31, 32). In
addition, FAK has been implicated in adhesion-dependent cell
survival (33, 34), while CAK has been implicated in cell death
pathways (35, 36). In neurons, the integration of FAK and
CAK-mediated signals may promote neurite outgrowth and
differentiation, and CAK may play a unique role in mainte-
nance of plasticity through modulation of ion channels (25, 37,
38). These results suggest that FAK and CAK may have both
common and distinct functions.
Although FAK and CAK are highly homologous, bind to a
common subset of proteins, and are capable of initiating a
subset of common signaling pathways, they clearly have
unique and perhaps complementary roles in the cell. Subtle
differences in mode of activation, regulation, subcellular local-
ization, catalytic activity, substrate preference, and/or scaffold-
ing activity appear to be critical determinants of differential
signaling. In order to define the molecular basis of these subtle
yet critical differences, we have constructed, expressed, and
characterized a complete set of six chimeric FAK/CAK pro-
teins in chick embryo cells. CAK exhibited higher catalytic
activity than FAK in an in vitro kinase assay. Furthermore,
chimeric kinases revealed that coupling of the FAK N terminus
and CAK catalytic domain yielded a highly active kinase,
suggesting that the N terminus of FAK family kinases may be
involved in regulation of catalytic activity. Substrate phospho-
rylation by chimeric kinases in vivo correlated perfectly with
catalytic activity in vitro, providing a molecular basis for dif-
ferential substrate phosphorylation by FAK and CAK in vivo.
This analysis revealed a potential role for the N terminus in
modulating subcellular localization, since chimeras with the
FAK N terminus and CAK C terminus targeted to focal ad-
hesions, whereas chimeras with both the N- and C termini of
CAK did not. The CAK N terminus also mediated striking
changes in cell morphology that were independent of changes
RhoA activity. Although it was not strictly required, targeting
to focal adhesions enhanced the ability of this domain to alter
morphology.
EXPERIMENTAL PROCEDURES
Cells, Viruses, and Plasmids—Chick embryo (CE) cells were isolated
from 9-day-old embryos and maintained as described previously (39).
For expression of exogenous proteins in CE cells, constructs were sub-
cloned into a replication competent avian retroviral vector, RCAS A
(40). RCAS A constructs were transfected into CE cells using the cal-
cium phosphate method as described (39) or LipofectAMINE Plus (In-
vitrogen) according to the manufacturer’s recommended protocol. Ex-
pression of RCAS A-encoded exogenous proteins was evaluated 7–9
days post-transfection. For co-expression with c-Src, cells expressing
wild type or chimeric FAK family kinases were infected with RCAS B
c-Src virus on day 5 post-transfection and lysed on day 10 post-trans-
fection as described previously (41). pCMV-Myc RhoA Q63L and pCMV-
Myc RhoA T19N plasmids, which were the generous gifts of Dr. Krister
Wennerberg, were transfected using LipofectAMINE Plus and analyzed
3 days post-transfection. Cell cultures were viewed using a Nikon TMS
inverted microscope and imaged using a Nikon CoolPix 950 digital
camera (100 magnification).
PCR Mutagenesis and Cloning—The DNA sequence corresponding to
the FAK N terminus (amino acids 1–332), catalytic domain (332–690),
and C terminus (690–1038), and the CAK N terminus (1–336), cata-
lytic domain (336–693), and C terminus (693–1009) were amplified
using PCR. At the junctions of these domains, restriction sites were
created. The N termini of FAK and CAK were amplified with N- and
C-terminal BamH1 sites. The catalytic domains were flanked by an
N-terminal BamH1 site and C-terminal EcoR1 site. The C-terminal
fragments were flanked by an N-terminal EcoR1 site and C-terminal
SalI site. pBluescript KS/FAK and pBluescript SK/CAK (7, 42)
were used as templates, and VENT polymerase (New England Biolabs,
Beverly, MA) was used for PCR. Both template constructs had a
C-terminal KT3 epitope tag, and therefore all resultant chimeric mol-
ecules were also C-terminal tagged. Fragments were ligated to generate
sequences that encoded eight chimeric proteins, each maintaining the
three-domain structure. The clones were named using a three-letter
system corresponding to the three domains in the chimeric protein. The
FFF and CCC clones were reconstituted FAK and CAK molecules that
contained the restriction sites that were engineered using PCR.
Chimeric constructs were subcloned into RCAS A for expression in CE
cells. All amplified fragments were sequenced at the UNC-CH Auto-
mated DNA Sequencing Facility on a model 377 DNA Sequencer
(PerkinElmer, Applied Biosystems Division) using the ABI PRISMTM
Dye Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq
DNA Polymerase, FS (PerkinElmer). Two unintended substitutions in
FAK led to amino acid changes: amino acid substitutions R724W and
A872G. These mutations, as well as the mutations engineered to create
restriction sites, were inconsequential in our analysis since the FFF
and CCC chimeras behaved like wild type FAK and CAK, respectively.
Antibodies—The following antibodies were used for immunoprecipi-
tation, immunoblotting, and/or indirect immunofluorescence. The KT3
monoclonal antibody (43), which recognizes the C-terminal KT3 epitope
tag on FAK, CAK, and chimeric proteins, was the kind gift from Dr.
J. T. Parsons (University of Virginia, Charlottesville, VA). A commer-
cially available KT3 antibody was used for indirect immunofluorescence
(Covance, Princeton, NJ). Monoclonal antibody RC20 (Transduction
Labortatories, San Diego, CA) and polyclonal phosphospecific antibod-
ies anti-PYK2 (pY402) and anti-PYK2 (pY579/580) (BIOSOURCE Inter-
national,Camarillo, CA) were used to detect phosphotyrosine. Mono-
clonal antibody anti-RhoA was purchased from Transduction
Laboratories. Anti-Src monoclonal antibody EC10 was purchased from
Upstate Biotechnology (Lake Placid, NY). Monoclonal anti-Myc anti-
body (clone 9E10) was purchased from Sigma. Polyclonal antibody
8605, which recognizes paxillin, was previously described (44).
Rhodamine-conjugated goat anti-mouse and fluorescein-conjugated
donkey anti-rabbit antibodies were used for indirect immunofluores-
cence (Jackson ImmunoResearch Laboratories, West Grove, PA). The
AlexaFluor 488-conjugated anti-BrdUrd antibody (Molecular Probes,
Eugene, OR) was used for analysis of cell cycle progression.
Cell Lysis, Protein Analysis, and Immunoprecipitation—Confluent
monolayers of cells were lysed in ice-cold Triton X-100/radioimmune
precipitation assay buffer as described (44). Lysates were clarified, and
protein concentrations were determined using the bicinchoninic acid
(BCA) assay (Pierce). For immunoprecipitations, the paxillin antibody
(2 ug), the KT3 antibody (6 ug), or the EC10 antibody (7 ug) were
incubated with 0.2–0.8 mg of cell lysate at 4 °C for 1 h. Immune
complexes were precipitated at 4 °C for 1 h with protein A-Sepharose
beads (Sigma), anti-mouse IgG-agarose beads (Sigma), or protein
A-Sepharose beads coated with AffiniPure rabbit anti-mouse IgG
(Jackson ImmunoResearch Labs). Immune complexes were washed
twice with ice-cold lysis buffer, and once with ice-cold PBS. Beads were
resuspended in Laemmli sample buffer and boiled to elute the proteins
(45), and the samples were analyzed by Western blotting.
In Vitro Kinase Assays—Kinases were overexpressed in CE cells and
immunoprecipitated as described above with minor modifications. To
compensate for differences in expression level and to promote recovery
of comparable amounts of each kinase, some chimeric proteins were
immunoprecipitated from more lysate. Specifically, FAK, CAK, FFF,
FFC, FCF, FCC, and CCC were immunoprecipitated from 0.4 mg of
lysate, whereas mock, CCF, CFC, and CFF were immunoprecipitated
from 0.8 mg of lysate. Immune complexes were washed two times with
ice-cold lysis buffer, once with ice-cold PBS, and once with kinase
reaction buffer (20 mM PIPES, pH 7.2, 3 mM MnCl2). Each reaction was
resuspended in 20 l of kinase reaction buffer supplemented with 10
Ci of [-32P]ATP (PerkinElmer Life Sciences). The reactions were
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incubated at room temperature with periodic mixing for 10 min. The
reaction was stopped by adding 20 l of 2 Laemmli sample buffer and
boiled to elute the protein. Samples were resolved on an SDS-polyacryl-
amide gel. The gel was dehydrated and exposed to film to reveal phos-
phorylated species.
Immunofluorescence—Glass coverslips were coated with 50 g/ml
bovine plasma fibronectin (Sigma) in PBS for 1 h at 37 °C. Cells were
plated onto the coated coverslips and maintained at 37 °C for 16 h. Cells
were fixed in 3.7% formaldehyde in Universal Buffer (UB; 20 mM Tris,
pH 7.6, 150 mM NaCl) for 8 min, washed twice in UB, permeabilized
with 0.5% Triton X-100 in UB for 5 min, and washed twice more in UB.
Coverslips were incubated with primary antibody (KT3, 1:1000; 8605,
1:800) diluted in UB for 1 h at 37 °C in a humidified chamber, washed
twice, and incubated with secondary antibody (anti-mouse rhodamine
and anti-rabbit fluorescein, 1:1000) diluted in UB for 1 h at 37 °C in a
humidified chamber. Coverslips were washed twice in UB and once
with distilled water, and mounted on slides for visualization using a
Leitz Orthoplan fluorescence microscope. Images were captured using a
Hamamatsu digital camera and Metamorph imaging software (Univer-
sal Imaging Corporation, West Chester, PA).
RhoA Activity Assay—The level of RhoA activity in CE cells was
assessed as previously described (46). Briefly, lysates made from con-
fluent mock-transfected and CCF-expressing cells were incubated with
a GST-Rhotekin RBD fusion protein bound to glutathione-agarose
beads (Sigma). Complexes were washed and Western blotted with anti-
RhoA and anti-Myc antibodies to reveal the amount of precipitated
RhoA. As controls, CE cells were transfected with Myc-tagged RhoA
Q63L (constitutively active) or RhoA T19N (dominant negative) and
analyzed in parallel.
Apoptosis Assay—In order to assess apoptosis, the Apoptag Plus
Fluorescein in situ apoptosis detection kit was used as recommended by
the manufacturer (Intergen Company, Purchase, NY). Briefly, CE cells
expressing wild type and chimeric kinases were plated on fibronectin-
coated coverslips as described above and grown to confluence over 2
days. As a positive control for apoptosis, mock-transfected cells were
treated with 1 M staurosporine (Sigma) for at least 4 h. Cells were
fixed in 3.7% formaldehyde in PBS and permeabilized in ethanol/acetic
acid (2:1) at 20 °C. Coverslips were then incubated with a fluorescein-
conjugated anti-digoxigenin antibody, and 4-6-diamidino-2-phenylin-
done dihydrochloride (DAPI, 1 g/ml, Molecular Probes, Eugene, OR) to
counterstain the nuclei. Coverslips were mounted onto glass slides and
visualized as described for immunofluorescence experiments. In each
experiment, 200 cells were counted, and the percentage of apoptotic
cells was determined.
Cell Cycle Progression Assay—Differences in the rate at which
starved CE cells expressing wild type and chimeric constructs entered
S-phase following serum stimulation was assessed. Briefly, cells were
plated onto fibronectin-coated coverslips at low density (25% conflu-
ence) and incubated overnight in complete media. Cells were then
starved in Dulbecco’s modified Eagle’s medium (DMEM) 0.2% chick
serum (Invitrogen) for 48 h. After rinsing twice with DMEM, complete
CE media (DMEM5% fetal bovine serum (Sigma), 1% chick serum)
supplemented with 100 M BrdUrd (5-bromo-2-deoxyuridine, Sigma)
was added back to the cells. As a control, one coverslip was incubated in
serum-free media supplemented with BrdUrd to verify that serum
starvation had arrested the cell cycle. After 16 h, cells were fixed in
3.7% formaldehyde in PBS and permeabilized in 0.5% Triton X-100 in
PBS. Coverslips were blocked in 2% bovine serum albumin in PBS for
1 h and subsequently treated with 0.1 unit/l DNase (Promega, Madi-
son, WI) for 30 min at 37 °C. Slips were incubated serially with anti-
BrdUrd antibody (1:20), KT3 (1:500), and finally, a mixture of rhodam-
ine-conjugated anti-mouse antibody (1:500) and DAPI (1 g/ml) for 1 h
each at 37 °C, with washing following each antibody step. Coverslips
were then rinsed in water, mounted onto glass slides, and visualized as
described for indirect immunofluorescence. In each experiment, 200
cells were counted, and the percentage of cells that had entered S phase
was determined.
RESULTS
Construction of Chimeric Molecules—In order to determine
the molecular basis of the functional differences between FAK
and CAK, a set of chimeric FAK/CAK molecules was con-
structed (Fig. 1). The three major domains of FAK and CAK
were individually amplified by PCR. Restriction sites were
created at the N and C termini of each domain to allow for
assembly of the domains into chimeric molecules (Fig. 1, upper
panel). The central domains, which are referred to as the cat-
alytic domains in this manuscript, include both the catalytic
FIG. 1. Schematic diagram of FAK/CAK chimeric proteins.
Chimeric molecules were built as described under “Experimental Pro-
cedures.” Upper panel, N-terminal, catalytic, and C-terminal domains
of FAK (stippled boxes) and CAK (shaded boxes) were individually
amplified using PCR. The catalytic domains of the chimera contained
the catalytic domains and Src binding sites (FAK pY397 and adjacent
proline-rich region; CAK pY402). Each construct had a C-terminal KT3
epitope tag. Lower panel, chimeric molecules were named using a three-
letter system. The three letters correspond to the three domains that
constitute the chimeric protein. F represents a FAK domain (stippled)
and C represents a CAK domain (shaded). FFF and CCC are recon-
stituted FAK and CAK molecules that also contain the engineered
restriction sites at the domain joints. Gray boxes, phosphotyrosine;
striped boxes, proline-rich regions; FAT, focal adhesion targeting
domain.
FIG. 2. Catalytic activity of FAK/CAK chimeric kinases in
vitro. Cell lysates were made from mock-transfected CE cells or cells
expressing FAK, CAK, or FAK/CAK chimeric proteins. Kinases were
immunoprecipitated with the KT3 antibody. To compensate for differ-
ences in levels of protein expression, FAK, CAK, FFF, FFC, FCF, FCC,
and CCC were immunoprecipitated from 400 g of lysate and mock,
CCF, CFC, and CFF were immunoprecipitated from 800 g of lysate.
Upper panel, one-half of each sample was subjected to an in vitro kinase
assay as described under “Experimental Procedures.” Kinase reactions
were separated by SDS-PAGE, and incorporation of 32P into the kinases
was visualized by autoradiography. Lower panel, the second half of each
immunoprecipitation was separated by SDS-PAGE and immunoblotted
with the KT3 antibody to show the amount of kinase present in each
reaction.
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domains and the binding sites for the Src SH2 and SH3 do-
mains (8, 47–49). A KT3 epitope tag was engineered at the C
terminus of each construct. Domains were assembled to gener-
ate a full set of chimeric proteins that retain the overall size
and structure of the kinase. Chimeric proteins were named
using a three-letter system (Fig. 1, lower panel) corresponding
to the three domains, where an F represents a FAK domain and
a C represents a CAK domain. Creation of restriction sites
resulted in amino acid substitutions at the joints of the chi-
meric proteins. To control for the presence of these substitu-
tions, two constructs, FFF and CCC, were built. These corre-
spond to wild type FAK and CAK except that they contain the
engineered restriction sites at the domain joints. The chimeric
constructs were subcloned into RCAS A, a replication-compe-
tent avian retroviral vector, for expression in chick embryo
(CE) cells. In order to verify the domain structure of chimeric
proteins, a panel of antibodies that recognized specific domains
of FAK and CAK was used to probe Western blots of chimera-
expressing CE cell lysates.2 The results confirmed the pre-
dicted domain structure of chimeric FAK/CAK proteins.
Catalytic Activity of FAK/CAK Chimeric Molecules in
Vitro—CAK expression in CE cells results in greater sub-
strate phosphorylation than expression of FAK (7). To explore
whether differences in intrinsic catalytic activity could explain
this result, the catalytic activity of FAK, CAK, and FAK/
CAK chimeric kinases was assessed in an in vitro immune
complex kinase assay. From lysates made from confluent mock-
transfected CE cells and cells expressing FAK, CAK, and the
chimeric proteins, kinases were immunoprecipitated using the
KT3 epitope tag antibody. One-half of each immune complex
was incubated with [-32P]ATP in kinase reaction buffer for 10
min and separated by SDS-PAGE. Incorporation of 32P into the
kinases was detected by autoradiography (Fig. 2, upper panel).
The other half of the immune complex was separated by SDS-
PAGE and Western blotted with the KT3 antibody to reveal the
amount of kinase in each reaction (lower panel). Under these
assay conditions, CAK exhibited higher catalytic activity than
FAK. This result is accentuated by the fact that less CAK was
present in the reaction than FAK. The catalytic activity of
control chimeric proteins FFF and CCC were similar to FAK
and CAK, respectively, demonstrating that amino acid sub-
stitutions in the chimeric kinases did not alter catalytic activ-
ity. Overall, chimeric proteins that contained the catalytic do-
main of CAK (including FCF, FCC, and CCF) exhibited higher
autophosphorylation activity than those that contained the
FAK catalytic domain (including FFC, CFC, and CFF). Unex-
pectedly, juxtaposition of the FAK N terminus and catalytic
domain of CAK (i.e. FCF, FCC) resulted in an enhancement of
catalytic activity above that of CAK itself. However, there was
no apparent change in activity when the N terminus of CAK
was combined with the FAK catalytic domain (compare FAK,
CFC, and CFF). These data implicate the catalytic domain as
the principal determinant of catalytic activity in vitro and
suggest that CAK may have higher intrinsic catalytic activity
relative to FAK. Furthermore, these results revealed a poten-
tial modulatory role for the N terminus. This is the first report
of a direct comparison of FAK and CAK catalytic activity in
vitro, and identifies a biochemical basis for differential sub-
strate phosphorylation in vivo.
Tyrosine Phosphorylation of Chimeric Kinases and Sub-
strates in Vivo—It was previously shown that in adherent CE
cells, CAK expression elicited higher levels of whole cell phos-
photyrosine than FAK expression. The major substrates that
were differentially phosphorylated were paxillin, p130cas, and
tensin. Interestingly, the basal level of FAK phosphorylation
was high, whereas that of CAK was very low (7). These phos-
phorylation events were investigated further using FAK/CAK
chimeric kinases. Lysates were made from confluent cultures of
mock-transfected CE cells and cells expressing FAK, CAK,
and chimeric FAK/CAK proteins. To compare cellular phos-2 J. Dunty and M. Schaller, unpublished observations.
FIG. 3. Tyrosine phosphorylation of substrates and FAK/CAK chimeric kinases in vivo. Cell lysates were made from mock-transfected
CE cells or cells expressing FAK, CAK, or FAK/CAK chimeric proteins. A, whole cell lysates (30 ug) were separated by SDS-PAGE, transferred
to nitrocellulose, and Western blotted to reveal tyrosine-phosphorylated species (upper panel). The membrane was stripped and reprobed with the
KT3 antibody to show the level of kinase expression (lower panel). B, paxillin was immunoprecipitated and Western blotted for phosphotyrosine
(upper panel). The membrane was stripped and reprobed to show the amount of paxillin in each lane (lower panel). C, wild type and chimeric
kinases were immunoprecipitated from cell lysates using the KT3 antibody. Immune complexes were Western blotted with an anti-phosphotyrosine
antibody (upper panel) and stripped and reprobed with the KT3 antibody to reveal the amount of kinase in each lane (lower panel).
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photyrosine profiles, whole cell lysates (30 g) were Western
blotted with an anti-phosphotyrosine antibody (Fig. 3A, upper
panel). The membrane was stripped and reprobed with the KT3
antibody to reveal the relative amount of exogenous kinase in
each lysate (lower panel). Paxillin was also immunoprecipi-
tated from these lysates. The immune complexes were Western
blotted for phosphotyrosine (Fig. 3B, upper panel) and stripped
and reprobed for paxillin to verify equal protein loading (lower
panel). As previously described (7), FAK expression had little
effect on cellular phosphotyrosine, whereas CAK expression
induced the phosphorylation of several species (Fig. 3A). Like-
wise, paxillin phosphorylation was only slightly elevated in
cells expressing FAK but was dramatically increased in CAK-
expressing cells (Fig. 3B). Importantly, FFF and CCC behaved
as wild type FAK and CAK in these experiments, suggesting
that amino acid substitutions within the chimeric proteins did
not alter biochemical activity in vivo. Similar to FAK, expres-
sion of chimeric proteins that contained the FAK catalytic
domain resulted in little change in cellular phosphotyrosine or
paxillin phosphorylation (Fig. 3, A and B; FFC, CFC, and CFF).
Chimeric kinases that contained the CAK catalytic domain
were as efficient or more efficient than CAK in elevating
cellular phosphotyrosine and paxillin phosphorylation (Fig. 3,
A and B; FCF, FCC, and CCF). Interestingly, the N terminus
modified substrate phosphorylation in vivo, since chimeras con-
taining the FAK N terminus induced greater levels of cellular
phosphotyrosine and paxillin phosphorylation than their coun-
terparts containing the CAK N terminus (Fig. 3, A and B,
compare FFF and CFF, FFC and CFC, FCF and CCF, FCC and
CCC). Furthermore, the combination of the FAK N terminus
and the CAK catalytic domain resulted in the most potent
induction of substrate phosphorylation (Fig. 3, A and B; FCF
and FCC). Tyrosine phosphorylation of p130cas and tensin was
also examined by immunoprecipitation and Western blot anal-
ysis, and the results were similar to those seen with paxillin.2
Therefore, levels of whole cell phosphotyrosine and paxillin
phosphorylation were determined primarily by the catalytic
domain, whereby the CAK catalytic domain was more effi-
cient than that of FAK in elevating cellular phosphotyrosine. In
addition, the N terminus of the kinase may modify catalytic
activity in vivo. Significantly, the level of substrate phospho-
rylation induced by the kinases in vivo correlates well with
catalytic activity in vitro (refer to Fig. 2).
In CE cells growing in culture, FAK is heavily phosphoryl-
ated on tyrosine while CAK exhibits very low phosphorylation
(7). To define the domains that mediate this dissimilarity, the
phosphorylation state of chimeric FAK/CAK proteins in vivo
was determined. Kinases were immunoprecipitated using the
KT3 antibody and Western blotted for phosphotyrosine (Fig.
3C, upper panel). The membrane was stripped and reprobed
with the KT3 antibody to reveal the amount of protein in each
lane (Fig. 3C, lower panel). As previously reported, FAK was
heavily phosphorylated in cells growing in culture, whereas the
basal level of tyrosine phosphorylation on CAK was low (7).
Likewise, FFF phosphorylation was high, and CCC phospho-
rylation was low. Phosphotyrosine on FCF and CFF was equiv-
alent to FAK. FCC phosphorylation was similar to CAK. The
remaining chimeric proteins, including FFC, CCF, and CFC,
exhibited an intermediate level of phosphorylation. Tyrosine
phosphorylation in vivo correlated best with the C terminus;
chimeras containing the FAK C terminus (i.e. FFF, FCF, CCF,
and CFF) were more highly phosphorylated on tyrosine than
their counterparts that contained the CAK C terminus (i.e.
FFC, FCC, CCC, and CFC, respectively). In addition, chimeric
proteins containing the FAK catalytic domain were phospho-
rylated slightly better than those containing the CAK cata-
lytic domain. Thus, the C terminus and catalytic domains are
the primary and secondary determinants, respectively, of tyro-
sine phosphorylation in vivo. It is noteworthy that the level of
tyrosine phosphorylation on chimeric FAK/CAK kinases cor-
relates with neither the relative catalytic activity in vitro nor
the ability to induce substrate phosphorylation in vivo.
Coupling of Chimeric Kinases with Src in Vivo—FAK and
Src family kinases act coordinately to send downstream signals
in the cell. Therefore, the ability of FAK kinases to send strong
signals downstream in vivo may be attributable to both high
intrinsic catalytic activity and increased coupling to Src. In
order to study this interaction, the ability of wild type and
chimeric kinases to co-immunoprecipitate with exogenously
expressed c-Src was determined. Lysates were made from con-
fluent cultures of CE cells expressing c-Src alone (Mock) or
co-expressing c-Src and FAK/CAK chimeric kinases. From
these lysates, c-Src was immunoprecipitated, and the immune
complexes were split in half. One-half was Western blotted
with the KT3 antibody to reveal the amount of co-immunopre-
cipitated chimeric kinases (Fig. 4A, upper panel). The other
half was blotted with the EC10 antibody to verify equal recov-
ery of Src in the immunoprecipitates (lower panel). A greater
amount of FAK was found in complex with c-Src than CAK,
and likewise more FFF was found in complex with c-Src than
CCC. Chimeras containing the FAK catalytic domain (FFF,
FIG. 4. Coupling of chimeric kinases with c-Src. A, cell lysates
were made from CE cells expressing c-Src alone (mock) and cells coex-
pressing c-Src and FAK, CAK, or FAK/CAK chimeric proteins. From
these lysates, c-Src was immunoprecipitated, and the immune com-
plexes were split in half. One-half was separated on an 8% gel and
Western blotted with the KT3 antibody to reveal co-precipitated wild
type and chimeric kinases (upper panel). The second half was separated
on a 12% gel and Western blotted for c-Src (lower panel). As a control,
FFF lysate was incubated with secondary antibody conjugated to beads
alone (2° alone). To distinguish between c-Src and the antibody heavy
chain, antibodies used for the immunoprecipitation were incubated
with buffer and analyzed in parallel (1°  2° Ab). B, cell lysates were
made from mock-transfected CE cells or cells expressing FCF, FCC,
CCC, or CCF. Kinases were immunoprecipitated with the KT3 anti-
body. To compensate for differences in levels of protein expression, FCF
and FCC were immunoprecipitated from 400 g of lysates, and mock,
CCC and CCF were immunoprecipitated from 800 g of lysate. The
immune complexes were split into thirds and Western blotted for phos-
phorylated Tyr402 (pY402), phosphorylated Tyr579/580 (pY579/580), and
phosphotyrosine (pY) as indicated. The pY blot was stripped and rep-
robed with the KT3 antibody to reveal the amount of immunoprecipi-
tated kinase.
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FFC, CFC, CFF) bound more efficiently to c-Src than those
bearing the CAK catalytic domain (FCF, FCC, CCC, CCF).
Note that the chimeras were built such that the central cata-
lytic domains included all c-Src binding sites. Thus, the cata-
lytic domain was the primary determinant of c-Src binding.
Among those kinases containing the CAK catalytic domain,
those that also contained the FAK N terminus (FCF, FCC)
bound better to c-Src than those containing the CAK N ter-
minus (CCC, CCF). This suggested that the N terminus of FAK
was permissive for c-Src binding in comparison to the CAK N
terminus. The major autophosphorylation site on FAK family
kinases also serves as the Src SH2-domain binding site. There-
fore, increased c-Src binding may be associated with elevated
phosphorylation at this site as well as sites that serve as Src
targets, such as the activation loop regulatory tyrosines. To
further examine their tyrosine phosphorylation, phosphospe-
cific antibodies were used to determine the level of phosphoryl-
ation on the major autophosphorylation site (Tyr402) and reg-
ulatory tyrosines in the activation loop (Tyr579/580) of chimeric
kinases containing the CAK catalytic domain (FCF, FCC,
CCC, and CCF). Kinases were immunoprecipitated using the
KT3 antibody, and immune complexes were split into thirds
and Western blotted for phosphorylated Tyr402 (pY402), phos-
phorylated Tyr579/580 (pY579/580), and phosphotyrosine (pY) as
indicated in Fig. 4B. The phosphotyrosine blot was stripped
and reprobed with the KT3 antibody to reveal the amount of
recovered kinase (Fig. 4B, lower panel). FCF and FCC exhib-
ited relatively higher levels of autophosphorylation than their
counterparts CCF and CCC, respectively (Fig. 4B, pY402), pro-
viding a molecular basis for increased Src binding to these
chimeras. Furthermore, FCF and FCC exhibited relatively
higher levels of activation loop phosphorylation than CCF and
CCC (Fig. 4B, pY579/580). Phosphorylation on activation loop
tyrosines is associated with increased catalytic activity (50, 51).
Induction of Morphological Changes by Selected FAK/CAK
Chimeric Proteins—Expression of CAK in CE cells results in
sporadic cell rounding within the confluent monolayer. Treat-
ment of these cells with sodium orthovanadate, a tyrosine
phosphatase inhibitor, results in severe disruption of the mono-
layer as evidenced by abundant cell rounding and loss of con-
fluence (7). Significantly, FAK expression has no effect on the
integrity of the monolayer, nor does treatment of FAK-express-
ing cells with sodium orthovanadate. In order to identify the
unique features of CAK that mediate changes in cell morphol-
ogy, the morphology of CE cells expressing FAK, CAK, and
FAK/CAK chimeric kinases was examined (Fig. 5). As pre-
dicted, expression of FAK or FFF had no effect on cell morphol-
ogy, whereas expression of CAK or CCC induced mild cell
rounding, in agreement with the previous report (7). FFC, FCF,
or FCC expression had little or no effect on cell morphology.
Surprisingly, in the absence of vanadate treatment, expression
of several chimeric proteins had striking effects on cell mor-
phology that were reminiscent of vanadate-treated CAK-
expressing cells. Cells expressing CFC were extremely elon-
gated and spindly, and some cell rounding was also induced.
Expression of CCF and CFF caused dramatic cell rounding,
where CCF was more potent than CFF. Furthermore, at the
time when changes in morphology were most striking, mono-
layers of CCF, CFC, and CFF-expressing cells seemed to take
longer to reach confluence than other chimera-expressing cell
cultures. These data implicate the N terminus of CAK in the
induction of changes in cell morphology. Furthermore, the
C terminus of FAK may cooperate with the N terminus of
CAK to promote the most dramatic alterations in morphology.
Morphological changes did not correlate with high catalytic
activity in vitro or an overall elevation of tyrosine phos-
phorylation in vivo.
Further Characterization of Cells that Exhibit Altered Cell
Morphology—The morphological changes that were observed
were intriguing, and could be due to alteration of a number of
cellular processes. Cells with altered morphologies, i.e. cells
expressing CCF, CFC, and CFF, were further analyzed to de-
termine the basis of these changes. Since CAK expression
promotes apoptosis in some cell types, (35, 36) the viability of
FIG. 5. Changes in cell morphology
induced by kinase expression. Mock-
transfected CE cells and cells expressing
FAK, CAK, or FAK/CAK chimeric pro-
teins were imaged using a Nikon TMS
inverted microscope and a Nikon CoolPix
950 digital camera (100 magnification).
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these cells was determined (Fig. 6A). At 7 days post-transfec-
tion, cells were plated onto fibronectin coverslips and allowed
to reach confluence over 2 days. Similar to cells grown on tissue
culture-treated dishes, dramatic morphological changes were
evident. As a positive control for apoptosis, mock-transfected
cells were treated with staurosporine. The percentages of apo-
ptotic and non-apoptotic nuclei were calculated. The number of
non-apoptotic mock-transfected cells was quite high (98.5 
1.1%). FAK (96.8  2.9%), FFF (99.4  0.7%), CAK (97.3 
2.1%), and CCC (98.7  0.6%) exhibited similar high levels of
non-apoptotic cells. Importantly, expression of chimeric ki-
nases that induced the greatest morphology changes did not
increase the rate of apoptotic cell death (CCF, 98.4  0.7%;
CFC, 97.1  2.3%; and CFF, 98.1  1.2%). Therefore, cell
rounding induced by chimera expression was not associated
with an elevation in the rate of apoptosis.
While FAK expression has been reported to accelerate cell
cycle progression, CAK expression had an opposing effect (32).
In order to assess whether expression of morphology-altering
chimeras was associated with a decreased rate of cell cycle
progression, a BrdU incorporation assay was employed (Fig.
6B). Serum-starved cells were stimulated with complete media
containing 100 M BrdUrd for 16 h, and the percentage of
BrdUrd-positive nuclei was determined. A low level of BrdUrd
incorporation was seen in serum-starved cells (8.3  2.8%).
Stimulation of mock-transfected cells with serum-containing
media prompted 38.5  7.2% of cells to enter S phase. At the
same time point, more FAK-expressing cells (55.3  3.1%) had
incorporated BrdUrd than mock cells, suggesting that, in
accordance with previous reports, FAK expression accelerated
S phase entry (31). However, in contrast to reports that it slows
cell cycle progression (32), CAK (48.7  5.1%) accelerated S
phase progression almost as well as FAK in CE cells. FFF and
CCC expression (59.3  6.4% and 49.5  2.6%, respectively)
mimicked the effects of FAK and CAK expression. Although
each chimeric kinase had a slightly different affect on cell cycle
progression, all cells entered S phase at a rate that was greater
than mock-transfected cells (CCF, 43.3  6.8%; CFC, 46.0 
7.8%; CFF, 48.3  7.6%). Therefore, altered cell morphology
and the apparent disruption of the monolayers were not due to
a cell cycle delay.
Subcellular Localization of Chimeric Proteins—In CE cells,
FAK is localized discretely to focal adhesions via its C-terminal
focal adhesion targeting (FAT) sequence. Although highly ho-
mologous to FAK within its putative FAT sequence region,
CAK localization is mainly diffuse in CE cells (7). In order to
elucidate the molecular mechanisms of differential subcellular
localization of FAK and CAK, indirect immunofluorescence
was used to study the localization of FAK/CAK chimeric pro-
teins in CE cells. Cells were plated onto fibronectin-coated
glass coverslips at low density and allowed to adhere and
spread for 16 h in complete media. Cells were then processed
and labeled with the KT3 antibody to reveal kinase localization
(Figs. 7 and 8). For the purposes of this analysis, only well
spread cells were studied.
Mock-transfected cells exhibited a nearly undetectable level
of nonspecific staining (Figs. 7 and 8, Mock). FAK was clearly
localized to focal adhesions, whereas CAK localization was
largely cytoplasmic (Figs. 7 and 8, FAK and CAK). In a small
percentage of cells, CAK was present in focal adhesions and/or
smaller focal adhesion-like structures. The control chimeras
FFF (Fig. 7) and CCC (Fig. 8) were localized as their wild type
counterparts, demonstrating that the amino acid substitutions
in the chimeric kinases did not alter subcellular localization. As
predicted, the FAK C terminus directed focal adhesion local-
ization of FCF, CCF, and CFF (Figs. 7 and 8). These results
demonstrate that the C terminus of FAK contains a potent
focal adhesion targeting sequence, since it can target the CAK
N terminus and catalytic domain (CCF) to focal adhesions. Like
CAK, CFC localization was diffuse (Fig. 8). However, quite
interestingly, the C terminus of CAK directed focal adhesion
localization when the N terminus of FAK was present (Fig. 7,
FFC and FCC). This suggested that the C terminus of CAK is
also sufficient to direct focal adhesion localization. Further-
more, substitution of the FAK N terminus may be permissive
for the focal adhesion targeting activity of the CAK C
terminus.
The morphology changes observed in cells expressing certain
chimeric kinases raised questions regarding the integrity of
their focal adhesions. To visualize focal adhesions, cells were
co-stained for paxillin (Fig. 8). Chimeric proteins that con-
tained the N terminus of FAK were well spread and exhibited
characteristic staining of paxillin in focal adhesions.2 Surpris-
ingly, even in apparently well spread cells expressing CAK,
CCC, CCF, CFC, and CFF, paxillin localization was altered to
varying degrees, suggesting that expression of these kinases
altered focal adhesion structure. The Rho family of GTPases
plays a central role in regulating the actin cytoskeleton (52). In
particular, Rho activity is important for generating tension
FIG. 6. Analysis of apoptotic cell death and cell cycle progres-
sion. A, mock-transfected CE cells and cells expressing FAK, CAK,
FFF, CCC, CCF, CFC, and CFF were plated onto fibronectin-coated
coverslips and grown to confluence at approximately day 7 post-trans-
fection. The percentage of non-apoptotic cells was assessed using the
Apoptag system as described under “Experimental Procedures.” The
data are a summation of four independent experiments. Error bars
represent S.D. B, mock-transfected CE cells and cells expressing FAK,
CAK, FFF, CCC, CCF, CFC, and CFF were adhered to fibronectin-
coated coverslips overnight and subsequently starved for 48 h in low
serum-containing media. Cells were then stimulated with complete
media containing 100 M BrdUrd for 16 h. Nuclei were scored for
BrdUrd incorporation as described under “Experimental Procedures.”
The data is expressed as percentage of BrdUrd-positive cells and are a
summation of three independent experiments. Error bars represent
S.D.
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which is associated with the formation of actin stress fibers and
focal adhesions (53). Therefore, the changes in cell shape and
focal adhesion structure observed in certain chimera-express-
ing cells might be mediated by down-regulation of Rho activity.
Since CCF cells exhibited the most dramatic morphological
changes, the level of activated, endogenous RhoA in mock and
CCF cells was assessed using the GST-RBD pull-down assay
(Fig. 9). The amount of active RhoA recovered from mock and
CCF cells was equal, suggesting that there was no difference in
the activation state of RhoA between these cells (Fig. 9, Rho
blot). As controls for this assay, RhoA Q63L (constitutively
active) and RhoA T19N (dominant negative) were analyzed.
The GST-RBD fusion protein bound to RhoA Q63L, but not
RhoA T19N (Fig. 9, Myc blot). Therefore, it appears that alter-
ation of cell morphology is not mediated by changes in RhoA
activity.
DISCUSSION
A comparative analysis of FAK and CAK revealed both
similarities and intriguing differences in their function (7). The
goal of this study was to define the sequences within FAK and
CAK that mediate their unique properties. Our approach was
to construct and comprehensively characterize a full set of
chimeric FAK/CAK proteins. Chimeric proteins have been
used previously to study the activities of FAK and CAK (14,
32, 35, 54). These studies have provided insight into selected
activities of FAK and CAK. However, additional valuable
information was obtained through the biochemical and biolog-
ical analysis of novel chimeric molecules. The results, which
are summarized in Table I, revealed an unexpected role for the
N-terminal domain in regulating substrate phosphorylation,
focal adhesion localization and cell morphology, and provided
an explanation for enhanced phosphorylation of substrates by
CAK relative to FAK.
Tyrosine phosphorylation of substrates in vivo correlated
perfectly with the origin of the catalytic domain, whereby the
catalytic domain of CAK induced greater levels of phosphoty-
rosine than the catalytic domain of FAK. Unexpectedly, the N
terminus had a striking impact on catalytic activity. Chimeras
with the N-terminal domain of FAK and catalytic domain of
CAK (FCF and FCC) elicited even higher levels of substrate
phosphorylation than CAK itself. The degree to which chi-
meric kinases elevated substrate phosphorylation in vivo was
proportional to their level of catalytic activity in an in vitro
kinase assay.
The mechanism by which the FAK and CAK catalytic do-
mains support different levels of catalytic activity is unclear.
One obvious possibility was that elevated catalytic activity was
the result of enhanced coupling to Src family kinases. Two lines
of evidence suggest that this was not the case. First, chimeras
with the FAK catalytic domain bound more c-Src, yet exhibited
lower activity in vitro. Second, the inclusion of PP2, a Src-
specific inhibitor (55) in the in vitro kinase assays had no effect
upon the autophosphorylation activity of the chimeras.2 Thus,
the presence of Src kinases in these immune complexes had a
negligible contribution to the observed differences in catalytic
activity in vitro. Rather, the intrinsic activity of the kinase
itself determines the baseline level of catalytic activity.
Interestingly, exchanging the CAK N terminus for the FAK
N terminus in the context of the CAK catalytic domain (i.e.
CCC, CCF to FCC, FCF) resulted in elevated c-Src binding.
Increased c-Src binding correlated with higher levels of cata-
lytic activity of these chimeras in vitro and in vivo. Further,
FCF and FCC exhibited higher levels of autophosphorylation
on Tyr402 and increased phosphorylation on activation loop
regulatory tyrosines Tyr579/580, which when phosphorylated,
promote maximal catalytic activity (50, 51). Therefore, modu-
lation of Src binding by the N terminus in the context of the
CAK catalytic domain was associated with elevated phospho-
rylation of key regulatory tyrosines, providing a potential
mechanism by which the N terminus may regulate catalytic
activity.
It was previously suggested that the N-terminal domain of
FAK kinases might impinge upon and negatively regulate cat-
alytic activity, since deletion of the N terminus of FAK led to
elevated catalytic activity in some cases (56, 57). However,
deletion of the N terminus in other cases has little effect upon
catalytic activity (18). A recent study of JAK3 also suggests a
mechanism by which the N-terminal FERM domain of FAK
kinases could regulate catalytic activity through an intramo-
lecular interaction. The N-terminal FERM domain of JAK3
FIG. 7. Subcellular localization of
chimeras containing the N terminus
of FAK. Mock-transfected CE cells and
CE cells expressing FAK, CAK, FFF,
FFC, FCF, and FCC were plated onto fi-
bronectin-coated coverslips and cultured
in complete media for 16 h. Cells were
then processed and labeled with the KT3
epitope tag antibody to reveal the local-
ization of the kinases as described under
“Experimental Procedures.”
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physically associates with the C-terminal kinase domain, and
this interaction is important for catalytic activity (58). Similar
intramolecular interactions within CAK or the chimera could
have inhibitory or stimulatory effects on catalytic activity. Al-
ternatively, the N terminus of CAK could recruit negative
regulators, e.g. phosphatases, or the N terminus of FAK may
recruit positive regulators into complex with the chimeras.
While the molecular details remain to be established, it is clear
that the presence of the N terminus of FAK with the catalytic
domain of CAK resulted in increased Src binding, which was
associated with pronounced effects on the tyrosine phosphoryl-
ation of these kinases, as well as their catalytic activity.
Tyrosine phosphorylation on the chimeric kinases correlated,
albeit not perfectly, with two domains: the C termini and cat-
alytic domains. Chimeric kinases containing the C-terminal
domain of FAK tended to be more highly phosphorylated. All
chimeras containing this domain efficiently targeted to focal
adhesions and thus enhanced tyrosine phosphorylation may be
due to subcellular localization. These results are consistent
with the conclusion drawn previously from a study using FAK/
CAK chimeric proteins (14). It has been suggested that local-
ization and complex formation in focal adhesions may be suf-
ficient for the activation and phosphorylation of FAK. This may
explain why CAK phosphorylation is low in cells in which it is
diffusely localized (14, 59). Interestingly, further analysis re-
vealed that localization to focal adhesions cannot be the sole
determinant of a high level of tyrosine phosphorylation, since
the FCC chimera targeted to focal adhesions, yet is poorly
tyrosine phosphorylated. Thus the C-terminal domain of FAK
may play a role in addition to targeting to promote tyrosine
phosphorylation.
The identity of the catalytic domain of the chimera also
contributed to levels of phosphotyrosine on chimeric kinases in
vivo. Chimeras with the FAK catalytic domain tended to be
more highly phosphorylated than chimeras with the CAK
catalytic domain, despite the fact that CAK catalytic activity
in vitro and in vivo is greater than that of FAK. Therefore,
relative tyrosine phosphorylation in vivo is not an indication of
relative catalytic activity. In support of this observation, a
previous report demonstrated that FAK catalytic activity was
low when NIH3T3 cells in culture were serum-starved, and
maximal after replating on fibronectin, although FAK was
highly phosphorylated in both cases (60). These data suggest
that the FAK catalytic domain could promote kinase phospho-
rylation via another mechanism. Since more c-Src was found in
complex with FAK than CAK, it is possible that FAK binds
Src kinases with a higher affinity than CAK, resulting in
elevated phosphorylation of Src-dependent sites on FAK/
CAK. FAK contains a consensus Src SH3 domain binding site
(368RALPSIPKL376) in the proximity of the Src SH2 domain
binding site which is not highly conserved in CAK (374NSLP-
QIPTL382). Alternatively, enhanced Src binding might impair
FIG. 8. Subcellular localization of chimeras containing the N
terminus of CAK. Mock-transfected CE cells and CE cells expressing
FAK, CAK, CCC, CCF, CFC, and CFF were plated onto fibronectin-
coated coverslips and cultured in complete media for 16 h. Cells were
co-stained with the KT3 epitope tag antibody to reveal kinase localiza-
tion and the anti-paxillin antibody 8605 to visualize focal adhesions.
FIG. 9. RhoA activity is similar in mock and CCF cells. The
activity of RhoA in confluent mock-transfected CE cells and cells ex-
pressing CCF, as well as cells expressing Myc-RhoA Q63L (constitu-
tively active, positive control) and Myc-RhoA T19N (dominant negative,
negative control) was assessed as described under “Experimental Pro-
cedures.” Membranes were Western blotted for Rho (upper panel) and
stripped and reprobed with anti-Myc antibody to reveal exogenous Rho
proteins (lower panel).
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dephosphorylation of the major autophosphorylation site
in vivo.
FAK and FRNK localize prominently to focal adhesions in
adherent cells (1). Conversely, there are conflicting reports
regarding the subcellular localization of CAK. The autono-
mously expressed C-terminal domain of CAK (CRNK/PRNK)
localizes to focal adhesions (7, 19). However, in CE cells, only a
subset (10%) of CAK expressing cells exhibit focal adhesion
staining. These data suggest that the FAT sequence within the
CAK C terminus is functional, but may be masked in the
context of the full length protein (7). Several groups have
employed FAK/CAK chimeric proteins to explore differences
in FAK and CAK localization. The FAK C terminus was
universally capable of directing chimeric kinases to focal adhe-
sions. Like CFF and CCF, chimeric proteins PFhy1 and Pyk2/
FAK-CT (which resemble CCF) were targeted to focal adhe-
sions (14, 32, 54). These results demonstrate that the FAK FAT
sequence was dominant over a potential opposing localization
signal in the CAK N terminus or catalytic domain.
While there is consensus that the FAT sequence of FAK can
target CAK to focal adhesions, there is conflicting data re-
garding the ability of the C terminus of CAK to target chi-
meric proteins to focal adhesions. Clearly, FFC and FCC local-
ized to focal adhesions in CE cells. The CAK FAT sequence
might be slightly less efficient than that of FAK since FFF and
FCF exhibited slightly more discrete focal adhesion localization
than FFC and FCC. That the C terminus of CAK can direct
focal adhesion targeting contrasts with previous reports of
chimeric proteins FPhy2 (similar to FFC) and FAK/Pyk2-CT
(similar to FCC), which were diffusely localized in NIH3T3
cells and FAK null cells, respectively (32, 54). Discrepant re-
sults regarding the localization of similar chimeric proteins
may reflect slight differences in domain structure or the use of
different cell systems. Since CE cells are primary cells that
form well-defined focal adhesions, we believe that it is a system
well suited for these analyses.
The C terminus of CAK was capable of directing chimeric
kinases containing the N terminus of FAK to focal adhesions
(FFC and FCC), but not those that contained the N terminus of
CAK (CCC and CFC). A potential explanation for this phe-
nomenon is that the N terminus of FAK houses a second focal
adhesion targeting activity that compensates for the absence of
a strong C-terminal CAK FAT sequence. In support of this
notion, the N terminus of FAK contains a 1 integrin binding
site (61). Additionally, the N termini of both FAK and CAK
contain a putative FERM domain, which has been implicated
in linkage to transmembrane proteins (3, 62, 63). However, an
ancillary targeting sequence in the N terminus of FAK must be
weak, since it cannot independently target FAK to focal adhe-
sions (18). Alternatively, the N terminus of CAK may oppose
the focal adhesion targeting activity of the C terminus of
CAK. The CAK N terminus could fold back onto the molecule
and block the FAT sequence. It may also direct the protein to or
anchor the protein in another location in the cell.
It was shown previously that treatment of cells expressing
CAK, but not FAK, with the tyrosine phosphatase inhibitor
vanadate induced dramatic changes in cell morphology (7). In
an effort to determine which domain of CAK mediated
changes in cell morphology, the morphology of cells expressing
chimeras was observed. Expression of kinases containing the N
terminus of CAK resulted in a profound loss of the typical
fibroblastic morphology. Strikingly, these morphological
changes occurred in the absence of vanadate. One explanation
for the morphology change is that expression of certain chime-
ras induced apoptosis. CAK is activated by a variety of stress
signals and has been directly implicated in signaling pathways
downstream of known apoptotic agents (25, 26, 36, 64). Fur-
ther, Xiong and Parsons (1997) showed that expression of
CAK/Pyk2 and chimeric proteins Pyk2/FAK1 and Pyk2/FAK2
(similar to CFF and CCF, respectively) in Rat-1 fibroblasts
resulted in apoptosis in a high percentage of cells. These data
suggested that the N terminus of CAK and catalytic activity
were required for maximum induction of cell death. Although
morphological changes that occur in CE cells are also depend-
ent upon the N terminus of CAK, cell rounding was not
associated with an increase in apoptotic cell death. Therefore,
it seems more likely that these kinases induce cell rounding by
eliciting changes in cytoskeletal structure.
The notion that FAK family kinases impinge upon the actin
cytoskeleton is not a new one. Both associate physically and
biochemically with actin-based structures and actin cytoskele-
ton regulatory proteins (1, 65). The importance of FAK family
kinases in regulation of the cytoskeleton is underscored by the
fact that FAK-null cells have increased stress fiber formation
and a transient migration defect. This affect has been attrib-
uted to a deregulation of Rho signaling (29, 66). Attenuation of
CAK expression in osteoclast-like cells causes cell retraction
and a dramatic decrease in the area of the cell (67). Similar to
CE cells, it was recently reported that CAK expression in-
duced cell rounding in Swiss 3T3 cells, and that this effect was
dependent upon the N terminus of the kinase. This morphology
was attributed to changes in actin cytoskeletal structure (68).
The mechanism by which chimeras containing the N termi-
nus of CAK mediate dramatic cell shape changes in CE cells
is unclear. The primary effect is not decreased adhesion or an
inability to spread, since there were no detectable difference in
the ability of these cells to initially attach or spread onto
fibronectin, and the kinetics of spreading were not altered.2
However, these cells may have a defect in maintenance of focal
adhesions or cell shape. This may be due to direct affects on the
structure of focal adhesions and/or the actin cytoskeleton. In
support of this hypothesis, paxillin staining was altered even in
well spread cells, suggesting that changes in focal adhesion













FFF     b
FFC     
FCF     
FCC     
CCC     
CCF     
CFC     
CFF     
a pY, tyrosine phosphorylation.
b None detected.
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esting to note that RhoA activity was unaltered in CCF cells,
suggesting that an alternate signaling pathway may be in-
volved in regulating cell morphology. The results in CE cells
are clearly phenomenological since CAK is not expressed in
this cell type. However, these finding may provide insight into
the physiological function of CAK in cells with dynamic cy-
toskeletons, such as macrophages and osteoclasts. The chal-
lenge for the future is to determine how FAK-like kinases
regulate changes in cell structure through elucidation of the
signaling pathways linking FAK kinases and cytoskeletal
dynamics.
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